CN108290904A - Elbasvir derivatives, the medical composition and its use containing the compound of deuterium modification - Google Patents

Elbasvir derivatives, the medical composition and its use containing the compound of deuterium modification Download PDF

Info

Publication number
CN108290904A
CN108290904A CN201680072055.0A CN201680072055A CN108290904A CN 108290904 A CN108290904 A CN 108290904A CN 201680072055 A CN201680072055 A CN 201680072055A CN 108290904 A CN108290904 A CN 108290904A
Authority
CN
China
Prior art keywords
compound
added
nmr
acid
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680072055.0A
Other languages
Chinese (zh)
Other versions
CN108290904B (en
Inventor
张寅生
敖汪伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN108290904A publication Critical patent/CN108290904A/en
Application granted granted Critical
Publication of CN108290904B publication Critical patent/CN108290904B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention belongs to field of medicaments, and in particular to elbasvir derivatives, the pharmaceutical composition containing the compound and its purposes in the drug for preparing treatment hepatitis c virus infection of deuterium modification.The elbasvir derivatives of the deuterium modification of the present invention are measured in one or more（Such as determination of activity, pharmacokinetics measurement, hepatomicrosome metabolic stability measure etc.）In there is superior property, be expected to reduce clinical dosage, to reduce treatment cost to allow more patients to be benefited.

Description

Elbasvir derivative, the medical composition and its use containing the compound of deuterium modification Technical field
The invention belongs to field of medicaments, and in particular to elbasvir derivative, the pharmaceutical composition containing the compound and its purposes in the drug of preparation treatment hepatitis c virus infection of deuterium modification.
Background technique
Many current drugs are absorbed, are distributed, are metabolized and/or are drained the puzzlement of (ADME) feature difference, and which hinders them widely to apply.ADME characteristic difference is also the big reason that drug candidate fails in clinical test.A strategy for having potential attraction for improving drug metabolism characteristic is to carry out deuterium modification.In this approach, the drug metabolism for slowing down CYP mediation by substituting one or more hydrogen atoms with D-atom is attempted.Deuterium is safe and stable, non-radiative hydrogen isotope.Compared to hydrogen, deuterium and carbon form stronger key.In selected example, bond strength increase that deuterium is given can the ADME characteristic to drug bring positive influences, generate and improve the potentially possible of pharmaceutical efficacy, safety and/or tolerance.Meanwhile because the size and shape of deuterium is substantially identical as hydrogen, compared to the precursor chemicals for only including hydrogen, the biochemical activity and selectivity of drug will not influence with deuterium substitution hydrogen.
Deuterium replace influence to metabolic rate reported on some drugs (for example, with reference to Blake, MI et al., J Pharm Sci, 1975,64:367-91；Foster,AB,Adv Drug Res,1985,14:1-40；Kushner, DJ et al., Can J Physiol Pharmacol, 1999,79-88；Fisher, MB et al., Curr Opin Drug Discov Devel, 2006,9:101-09), the result is that variable and uncertain.For some compounds, deuterate causes internal metabolite clearance to reduce.For other compounds, metabolism is not changed.For some compounds, it has therefore proved that metabolite clearance increases.The changeability of deuterium effect, which also results in expert's query or abandoned deuterium, modifies the idea for inhibiting detrimental metabolic as feasible drug design strategies (referring at Foster page 35 and at Fisher page 101).
Even if deuterium modification is also uncertain to the effect of the metabolic characteristic of drug when D-atom is integrated to the known site of metabolin.It only actually prepares and has detected deuterated drug, just can determine that whether and how metabolic rate is different from non-deuterated counterpart.For example, see Fukuto et al. (J.Med.Chem., 1991,34,2871-76).Many drugs have multiple possible sites that metabolic response occurs.It needs the site of deuterium substitution and makes the visible necessary degree of deuterium of the influence to metabolism, if any, each drug is all different.
It is a kind of compound monolithic once a day that the hepatitis of Mo Shadong takes orally cocktail grazoprevir/elbasvir (100mg/50mg) entirely, is made of grazoprevir (a kind of NS3/4A protease inhibitors) and elbasvir (a kind of NS5A polymerase inhibitors).FDA was granted by 2 new breakthrough drug (BTD) qualifications in 2015, was respectively as follows: the BTD qualification of 4 chronic hepatitis C viral of (1) therapeutic gene type (HCV GT4) the infected；(2) treatment is carrying out the BTD qualification of genotype 1HCV (HCV GT1) the infected of hemodialysis with end-stage renal disease.
Although elbasvir has favorable activity, it is desired nonetheless to which further exploitation has inhibitory activity to hepatitis C virus NS 5 A, can be used for preventing or treating the noval chemical compound of hepatitis c virus infection.
Summary of the invention
In the first aspect of the invention, one kind is provided such as formula Ι compound represented or its pharmaceutically acceptable salt:
Wherein, R1Or R2Separately it is selected from CH3、CH2D、CHD2Or CD3, R3、R4、R5、R6、R7、R8Or R9It is separately R selected from H (hydrogen) or D (deuterium), condition1~R9In contain at least one D-atom.
In some embodiments of the present invention, R1、R2It is simultaneously CH3Or CD3.In one embodiment of the invention, R1、R2It is simultaneously CH3.In another embodiment of the present invention, R1、R2It is simultaneously CD3。
In some embodiments of the present invention, R5、R6、R7、R8、R9It is simultaneously H or D.In one embodiment of the invention, R5、R6、R7、R8、R9It is simultaneously H.In another embodiment of the present invention, R5、R6、R7、R8、R9It is simultaneously D.
In certain preferred embodiments of the invention, the example such as formula Ι compound represented is as follows:
Compound R1 R2 R3 R4 R5 R6 R7 R8 R9
1 CD3 CD3 H H H H H H H
2 CD3 CD3 D H H H H H H
3 CD3 CD3 H D H H H H H
4 CD3 CD3 D H D D D D D
5 CD3 CD3 D D H H H H H
6 CD3 CD3 D D D D D D D
7 CH3 CH3 D H H H H H H
8 CH3 CH3 D D H H H H H
9 CH3 CH3 D H D D D D D
10 CH3 CH3 D D D D D D D
11 CH3 CH3 H D H H H H H
In further preferred embodiment of the present invention, the example such as formula Ι compound represented is as follows:
Term " pharmaceutically acceptable salt " refers to the salt for remaining the biological efficacy of the free bronsted lowry acids and bases bronsted lowry of specific compound without biology ill-effect.The example of pharmaceutically acceptable salt includes but is not limited to: (1) salt of the formation such as acid-addition salts and inorganic acid such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, phosphoric acid；Or the salt with the formation such as organic acids such as malic acid, fumaric acid, maleic acid, benzoic acid, phenylacetic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, hydroxyacetic acid, cinnamic acid, pyruvic acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, acrylic acid, mandelic acid；Or the salt of the formation such as (2) base addition salts and alkali metal such as lithium, sodium, potassium；With the salt of the formation such as alkaline-earth metal such as calcium, magnesium；With the salt of the formation such as organic bases such as ammonium, choline, diethanol amine, lysine, ethylenediamine, tert-butylamine, t-octanylamine, three (methylol) aminomethanes, N- methyl glucose osamine, triethanolamine, dehydroabietylamine.
If any atom of the compound of institute's labelled synthesis does not specify in the present invention, the stable isotope of any one of the atom can be represented.Unless stated otherwise, when position a certain in structure is defined as H i.e. hydrogen (H-1), which contains only naturally occurring isotopic mass.Equally, unless stated otherwise, when position a certain in structure is defined as D i.e. deuterium (H-2), the position is at least 3340 times bigger than naturally occurring isotopic mass (0.015%) (at least having 50.1% deuterium isotope) containing isotopic mass.
The deuterated rate of the compound of institute's labelled synthesis refers to the isotopic content of labelled synthesis and the ratio of naturally occurring isotopic mass in the present invention. Each of compound of institute's labelled synthesis specifies the deuterated rate of D-atom that can be at least 3500 times (52.5%) in the present invention, at least 4000 times (60%), at least 4500 times (67.5%), at least 5000 times (75%), at least 5500 times (82.5%), at least 6000 times (90%), at least 6333.3 times (95%), at least 6466.7 times (97%), at least 6566.7 times (98.5%), at least 6600 times (99%), at least 6633.3 times (99.5%).
Herein, any each atom for being not designated as deuterium is with the presence of its natural isotopic abundance.
The compound of the present invention can be prepared by the following method: i.e. the method (such as method disclosed in embodiment 189b (optional program)) with reference to disclosed in WO2010111483, and use deuterated reagent (such as CD3OD, D6- benzaldehyde, heavy water etc.) replace corresponding non-deuterated reagent.
It is another aspect of the present invention to provide a kind of pharmaceutical compositions, and it includes such as formula Ι compound represented or its pharmaceutically acceptable salt and pharmaceutically acceptable excipient.
It is a further aspect of the present invention to provide the purposes of compound shown in formula I or its pharmaceutically acceptable salt, the pharmaceutical composition containing compound shown in formula I or its pharmaceutically acceptable salt in the drug of preparation prevention or treatment hepatitis c virus infection.
It is a further aspect of the present invention to provide the pharmaceutical compositions containing compound or its pharmaceutically acceptable salt shown in formula I for preventing or treating hepatitis c virus infection.
Another aspect of the invention is to provide a kind of method prevented or treat hepatitis c virus infection, and the method includes compound shown in formula I or its pharmaceutically acceptable salt, the pharmaceutical composition containing compound shown in formula I or its pharmaceutically acceptable salt are given to the patient of needs.
The hepatitis C virus includes its Multi-genotype and several genes hypotype, such as 1a, 1b, 2a, 2b, 3a, 3b, 4a, 5a, 6a etc..
Compared with elbasvir, compound shown in formula I has superior property in one or more measurements (such as determination of activity, pharmacokinetics measurement, hepatomicrosome metabolic stability measure etc.), it is expected to reduce clinical dosage, to reduce treatment cost to allow more patients to be benefited.
Term used herein has following meaning:
Term " DMA " refers to DMAC N,N' dimethyl acetamide.
Term " B (Pin)2" refer to connection boric acid pinacol ester.
Term " Pd (dppf) Cl2" refer to [bis- (diphenylphosphine) ferrocene of 1,1'-] palladium chloride.
Term " HOBt " refers to I-hydroxybenzotriazole.
Specific embodiment
The preparation method of the present invention such as formula Ι compound represented is described more particularly below, but these specific methods do not form any restrictions to the present invention.Various synthetic methods describing in the present specification or known in the art can also optionally be combined and are easily made by the compounds of this invention, and such combination can be easy to carry out operation by those skilled in the art in the invention.
The preparation of 1 compound 1 of embodiment
The preparation of step (1) 3- bromophenyl -2- (2,5- dibromo phenyl) acetic acid esters
50g 2,5- dibromo phenylacetic acid, 600mL methylene chloride are added into 1000mL there-necked flask, 0.62g DMF is added after dissolved clarification, room temperature is added dropwise 28.3g oxalyl chloride, reacts at room temperature 1 hour after adding, then reaction solution is concentrated into about 250mL volume, obtains 2,5- dibromobenzene chloride solution.
31.5g m -bromoacetophenone is sequentially added into another 1000mL there-necked flask, 265mL methylene chloride, 36.6g 2 is added dropwise again, 6- lutidines (2,6-lutidine) keeps temperature to be lower than 25 DEG C, 0-5 DEG C is cooled to after adding, above-mentioned 2, the 5- dibromobenzene chloride solution prepared is added dropwise again, adds latter 0-5 DEG C and reacts 1 hour.It is quenched after reaction with 265mL 1N HCl, organic phase is washed with 265mL again, then organic phase is concentrated to and is added acetonitrile, be concentrated to get the acetonitrile solution of about 150mL volume, 180mL water is added dropwise, stirring 1 hour, filtering, filter cake are washed with 160mL acetonitrile/water (1:1), obtain 69.7g faint yellow solid after 50 DEG C of vacuum drying, that is compound 1-a, yield 90.6%.
1H-NMR(CDCl3, 300MHz): δ 7.54 (d, J=3.0Hz, 1H), 7.49 (d, J=10.6Hz, 1H), 7.39 (dd, J=10.0,2.4Hz, 1H), 7.35-7.32 (m, 2H), 7.25 (d, J=10.1Hz, 1H), 7.10 (dd, J=10.6,1.6Hz, 1H), 4.00 (s, 2H).
13C-NMR(CDCl3, 300MHz): δ 167.9,151.0,135.5,134.5,134.3,132.4,130.5,129.3,124.9,12 3.8,122.4, 121.4,120.4,41.5。
HRMS (M-H) m/z:444.8073.
The preparation of step (2) 1- (the bromo- 2- hydroxy phenyl of 4-) -2- (2,5- dibromo phenyl) ethyl ketone
7.9g methanesulfonic acid acid anhydride, 436g methanesulfonic acid, N are sequentially added into 1000mL there-necked flask265 DEG C are cooled to after being heated to 90 DEG C of reactions under protection 1 hour; 68g compound 1-a is added; 65 DEG C reaction 24 hours after be cooled to room temperature; it is added dropwise 572mL isopropanol/water (3:1), is filtered after stirring 20min after adding, filter cake is washed with 215mL isopropanol/water (1:1); the drying 12 hours of 60 DEG C of obtained solid; obtain 58.8g gray solid, i.e. compound 1-b, yield 86.5%.
1H-NMR (300MHz, DMSO-d6): δ 11.60 (s, 1H), 7.87 (d, J=8.5Hz, 1H), 7.67 (d, J=2.4Hz, 1H), 7.59 (d, J=8.7Hz, 1H), 7.45 (dd, J=8.7,2.4Hz, 1H), 7.26 (d, J=1.9Hz, 1H), 7.20 (dd, J=8.4,1.8Hz, 1H), 4.59 (s, 2H).
13C-NMR (300MHz, DMSO-d6): δ 199.3,160.7,138.4,135.5,134.5,132.6,132.1,129.2,124.5,12 3.0,121.5,120.9,120.8,47.9.
HRMS (M-H) m/z:444.8079.
The preparation of step (3) bromo- 2- of 5- (2- (2,5- dibromo phenyl) -1- iminoethyl) phenol
160mL 7M methanol ammonia, 28g compound 1-b are added into 500mL single port bottle, room temperature reaction is filtered after 24 hours, and the drying 8 hours of 40 DEG C of obtained solid obtains 23.8g yellow solid, i.e. compound 1-c, yield 85%.
1H-NMR(CDCl3, 300MHz): δ 9.97, (s, 1H), 7.56 (d, J=9.1Hz, 1H), 7.48 (d, J=8.6Hz, 1H), 7.42 (d, J=2.4Hz, 1H), 7.40 (d, J=2.4Hz, 1H), 7.22 (d, J=2.0Hz, 1H), 7.02 (dd, J=8.6,2.0Hz, 1H), 4.22 (s, 2H).
13C-NMR(CDCl3, 300MHz): δ 175.9,164.2,135.3,135.1,134.9,133.0,128.8,127.7,124.4,12 2.1,122.0,121.2,116.9,42.6.
HRMS (M+H) m/z:445.8385.
The preparation of step (4) (R) -2- (1- amino -2- (2,5- dibromophenol) ethyl) -5- bromophenol
130mL methylene chloride is added into 350mL pressure pipe, 11.5g compound 1-c, 3.56g ammonium formate, 47.7mg (R, R) Teth-TsDPEN-RuCl (AlfaAesar), 70 DEG C are reacted 24 hours.Then 10%NaHCO is used3Solution is neutralized to pH=7.5, and organic phase is concentrated after being washed with 2 × 20mL, and about 100ml acetonitrile is added, is concentrated to get about 60mL acetonitrile solution, and after being stirred at room temperature 1 hour, filtering obtains 10.43g gray solid, i.e. compound 1-d, yield 90.3% after vacuum drying.
1H-NMR(CDCl3, 300MHz): δ 7.46 (d, J=8.4Hz, 1H), 7.27 (m, 1H), 7.22 (d, J=2.4Hz, 1H), (7.06 d, J=1.9Hz, 1H), 6.87 (dd, J=8.1,2.0Hz, 1H), 6.70 (d, J=8.1Hz, 1H), 4.45 (dd, J=8.8,5.7Hz, 1H), 3.15 (m, 2H).
13C-NMR(CDCl3, 300MHz): δ 158.7,139.1,134.5,134.4,131.8,129.0,124.8,123.5,122.2,12 2.1,121.5,120.6,55.5,42.8.
HRMS (M+H) m/z:447.8542.
The preparation of the bromo- 2- of step (5) (R) -5- (5--bromo indole quinoline -2- base) phenol
21.35g compound 1-d, 452mg cuprous iodide is sequentially added into 250mL there-necked flask, 30.9g cesium carbonate, lower 45 DEG C of nitrogen protection are reacted 1 hour.Then 427mL ethyl acetate and 132mL saturated ammonium chloride solution is added, pH=7.5 is adjusted with 1N HCl again, water phase is extracted twice with 2 × 50mL ethyl acetate again, merges organic phase, then is washed respectively with 88mL 10%NaCl, 88mL, organic phase is concentrated into about 120mL acetonitrile solution, 120mL water is added dropwise, filtering obtains 13.13g gray solid after vacuum drying, that is compound 1-e, yield 75%.
1H-NMR(CDCl3, 300MHz): δ 9.58 (s, 1H), 7.31 (s, 1H), 7.25 (d, J=8.3Hz, 1H), 7.10 (d, J=2.0Hz, 1H), 6.98 (dd, J=8.0,2.0Hz, 1H), 6.90 (d, J=8.0Hz, 1H), 6.73 (d, J=8.0Hz, 1H), 4.94 (m, 1H), 4.40 (s, 1H), 3.30 (t, J=8.6Hz, 1H), 3.10 (dd, J=15.7,12.4Hz, 1H).
13C-NMR(CDCl3, 300MHz): δ 157.6,147.4,132.8,130.5,129.4,127.8,123.4,122.7,122.4,12 0.9,111.8,113.3,65.1,38.0.
HRMS (M+H) m/z:367.9269.
Bromo- 6- phenyl -12,12a- dihydro -6H- benzoyl [5,6] [1,3] the oxygen azepine of step (6) (S, 12aR) -3,10- twoThe preparation of [3,4-a] indoles
6g compound 1-e, 30mL acetonitrile is sequentially added into 100mL there-necked flask, 2.41g benzaldehyde, 93mg trifluoroacetic acid, lower 35 DEG C of nitrogen protection are reacted 3 hours.Then 2.75mL 5%NaHCO is successively added dropwise3Solution and 12mL water, filtering, filter cake successively use 18mL acetonitrile/water (2:1) and 12mL to wash, 6.66g gray solid, i.e. compound 1-f, yield 89.6% are obtained after vacuum drying.
1H-NMR(CDCl3, 300MHz): δ 7.58 (m, 2H), 7.40-7.36 (m, 4H), 7.23 (s, 1H), 7.08 (d, J=2.0Hz, 1H), 6.98 (dd, J=8.2,2.0Hz, 1H), 6.82 (m, 2H), 6.76 (s, 1H), 4.71 (d, J=8.9Hz, 1H), 3.52 (dd, J=15.7,8.9Hz, 1H), 3.12 (d, J=15.7Hz, 1H).
13C-NMR(CDCl3, 300MHz): δ 153.2,148.0,137.6,131.4,130.4,128.8,128.5,128.4,127.8,12 6.8,124.4,123.8,121.2,120.3,112.6,110.9,83.1,55.5,36.0.
HRMS (M+H) m/z:455.9577.
The bromo- 6- phenyl -6H- benzoyl [5,6] [1,3] of step (7) (S) -3,10- two is miscellaneousThe preparation of [3,4-a] indoles
6.66g compound 1-f, 67mL DMA, 3.67g NaHCO are sequentially added into 250mL there-necked flask3, 10 DEG C are cooled to, 4.4g potassium permanganate is added portionwise, then 16.7mL water is added dropwise, system temperature is kept to be lower than 15 DEG C, 10 DEG C of reactions are stayed overnight after adding.133mL ethyl acetate is added, then 67mL NaHSO is added dropwise3Aqueous solution, stratification, water phase uses 67mL ethyl acetate to extract again, merges organic phase, is washed three times with 3 × 33mL 10%NaCl solution, gained organic phase is concentrated to get about 67mL aqueous isopropanol, it is added dropwise after 67mL water is stirred overnight and filters again, filter cake is washed with 25mL isopropanol/water (1:1), and 5.62g solid is obtained after vacuum drying, that is compound 1-g, yield 84.8%.
1H-NMR(CDCl3, 300MHz): δ 7.81 (d, J=1.8Hz, 1H), 7.51 (d, J=8.1Hz, 1H), 7.37-7.28 (m, 3H), 7.21-7.17 (m, 3H), 7.11-7.08 (m, 3H), 6.85 (s, 1H), 6.70 (d, J=8.8Hz, 1H), 6.90 (d, J=8.0Hz, 1H), 6.73 (d, J=8.0Hz, 1H), 4.94 (m, 1H), 4.40 (s, 1H), 3.30 (t, J=8.6Hz, 1H), 3.10 (dd, J=15.7,12.4Hz, 1H).
13C-NMR(CDCl3, 300MHz): δ 150.0,136.2,133.9,132.1,130.7,123.0,126.8,125.6,125.1,12 3.4,122.4,121.3,117.0,114.2,111.2,96.8,84.5.
HRMS (M+H) m/z:453.9485.
Step (8) (2S, 2 ' S)-di-t-butyl 2,2 '-(5,5 '-((S) -6- phenyl -6H- benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles -3,10- diyl) two (1H- imidazoles -5,2- diyls)) two (pyrrolidines -1- formic acid esters) preparation
60mL Isosorbide-5-Nitrae-dioxane, 2.5g compound 1-g, 3.03g B (Pin) are sequentially added into 250mL there-necked flask2, 2.12g potassium acetate, 200mg Pd (dppf) Cl2, nitrogen protection it is lower 110 DEG C reaction 3 hours after cool, add 40mL Isosorbide-5-Nitrae-dioxane and 10mL water, 4.11g compound 1-h, 1.6g Pd (dppf) Cl2, 4.5g potassium carbonate, the lower 110 DEG C of reactions of nitrogen protection are overnight.The post-treated rear pillar chromatographic purifying (EA:PE=45:55) of reaction solution, obtains 2.74g yellow solid, i.e. compound 1-i, yield 66%.
1H-NMR (DMSO-d6,300MHz): δ 11.89 (m, 2H), 7.99 (s, 1H), 7.79 (d, 1H), 7.71 (s, 1H), 7.54-7.46 (m, 3H), 7.42-7.37 (m, 2H), 7.30-7.27 (m, 4H), 7.08 (s, 1H), 4.82 (m, 2H), 3.55 (br s, 2H), 3.37 (m, 2H), 2.32-2.10 (m, 2H), 2.08-1.83 (m, 6H), 1.41-1.16 (m, 18H).
13C-NMR (DMSO-d6,300MHz): δ 170.8,154.6,153.8,149.4,139.1,138.3,134.6,129.6,129.3,129.1,126.8,124.5,120.3,119.4,116.1,113.4,97.3,79.0,78.7,60.2,55.7,47.0,46.8,33.8,28.7,28.4,24.3,23.6,21.2,14.6.
HRMS (M+H) m/z:768.3887.
Step (9) 6- phenyl -3,10- two (2- ((S)-pyrrolidin-2-yl) -1H- imidazoles -5- base) -6H- benzoyl [5,6] [1,3] oxygen azepineThe preparation of [3,4-a] indole hydrochloride
2.7g compound 1-i, 15mL methanol, 2.8g concentrated hydrochloric acid are sequentially added into 250mL single port bottle, 45 DEG C reaction 4 hours after be cooled to room temperature, be added dropwise 45mL acetonitrile, filtered after being stirred overnight at room temperature, 2.18g solid, i.e. compound 1-j, yield 87.2% are obtained after vacuum drying.
1H-NMR (DMSO-d6,300MHz): δ 8.31 (d, J=0.7Hz, 1H), 8.21 (s, 1H), 8.19 (s, 1H), 8.05 (d, J=8.0Hz, 1H), 7.88 (s, 1H), 7.72 (m, 3H), 7.47 (d, J=8.8Hz, 1H), 7.32 (m, 4H), 7.02 (m, 1H), 5.16 (t, J=8.0Hz, 1H), 5.06 (t, J=8.0Hz, 1H), 3.52-3.37 (m, 4H), 2.57-2.47 (m, 5H), 2.24-2.17 (m, 2H), 2.08-1.91 (m, 2H).
13C-NMR (DMSO-d6,300MHz): δ 149.7,142.7,141.5,137.4,135.7,135.2,132.3,130.0,129.3,129.1,126.8,125.7,121.0,120.6,120.2,118.5,118.0,117.4,115.5,115.0,111.5,98.9,83.6,53.1,52.6,46.0,45.9,30.0,29.9,24.6,24.5.
HRMS (M+H) m/z:568.2780.
The preparation of step (10) (S) -2- ((three deuterium methoxycarbonyls) amino) -3 Methylbutanoic acid
9.94g triphosgene, 60mL chloroform are sequentially added into 250mL single port bottle, ice salt bath is cooled to 0 DEG C, adds 7.2g CD3Chloroform (20mL) solution of 10.16g triethylamine is added dropwise in OD, adds and moves back to room temperature reaction 2 hours, it is washed with 3 × 25mL ice water, is concentrated and does after anhydrous magnesium sulfate is dry, obtain 5.72g colourless liquid, that is three deuterium methylchloroformates are directly used in and react in next step.
54.3mL water, 2.17g sodium hydroxide are added into 100mL there-necked flask, 2.88g sodium carbonate adds 6.36g Valine, cools to 0 DEG C, above-mentioned tri- deuterium methylchloroformate of 5.72g is added dropwise, reacts at room temperature 3 hours after adding.Three times with the extraction of 3 × 25mL ether, water phase is cooled to 0 DEG C, adjusts pH=1~2 with concentrated hydrochloric acid, and then three times with the extraction of 3 × 80mL methylene chloride, concentration is dry after anhydrous magnesium sulfate is dry, obtains 3.942g white solid, i.e. compound 1-k, yield 40.8%.
1H-NMR (DMSO-d6,300MHz): δ 12.51 (s, 1H, ValCOOH), 7.29 (s, 1H, ValNH), 3.82~3.87 (m, 1H, ValCH), 2.00~2.04 (m, 1H, ValCH (CH3)3),0.87(d,6H,CH(CH3)2)。
13C-NMR (DMSO-d6,300MHz): δ 134.70,113.55,7.28,6.62,5.63,3.12.
HRMS (M+H) m/z:177.0923.
Step (11) two (three deuterium methyl) ((2S, 2 ' S)-((2S, 2 ' S) -2,2 '-(5,5 '-((S) -6- phenyl -6H- benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles-3,10- diyl) two (1H- imidazoles-5,2- diyls)) two (pyrrolidines-2,1- diyls)) two (3- methyl-1-butanone-2,1- diyls)) dicarboxylic acid esters preparation
500mg compound 1-j, 6mL acetonitrile is sequentially added into 50mL two-mouth bottle, is cooled to 5 DEG C, 274mg compound 1-k, 496mg N-methylmorpholine is added, and 47.3mg HOBt, 295mg EDCHCl is reacted at room temperature overnight after adding.8mL ethyl acetate is added thereto, uses 4mL 2M NH respectively4Cl is washed, 3mL 10wt%NaHCO3It washes, 3mL 10wt%Na2CO3It washes, 3mL washing, the dry organic phase of anhydrous magnesium sulfate, concentration rear pillar chromatography (MeOH:DCM=3:100) obtains 428mg yellow solid, i.e. compound 1, yield 68.8%, purity 96%, 99%de.
1H-NMR (DMSO-d6,300MHz): δ 8.13 (s, 1H), 8.10 (s, 1H), 8.07 (d, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.56-7.54 (m, 3H), 7.52 (d, 1H), 7.35 (s, 1H), 7.31-7.27 (m, 5H), 6.97 (m, 2H), 5.16 (t, 1H), 5.12 (t, 1H), 4.15-4.11 (m, 2H), 3.91-3.80 (m, 4H), 2.45-2.36 (m, 2H), 2.02-1.98 (m, 8H), 0.85 (d, 3H), 0.82 (d, 3H), 0.80 ( D, 3H), 0.77 (d, 3H).
13C-NMR (DMSO-d6,300MHz): δ 170.8,157.3,149.9,149.4,138.7,138.1,136.9,134.4,131.9,130.1,129.6,129.3,129.1,126.8,124.6,120.2,119.3,116.1,115.9,113.8,113.5,111.4,110.3,97.1,58.5,58.4,55.4,54.7,51.9,47.3,31.4,30.3,24.7,24.6,19.5,19.4,19.1,19.0.
HRMS (M+H) m/z:888.4388.
The preparation of 2 compound 9 of embodiment
Bromo- 6- phenyl -12,12a- dihydro -6D- five deuterium benzoyl [5,6] [1,3] the oxygen azepine of step (1) (S, 12aR) -3,10- twoThe preparation of [3,4-a] indoles
2.64g compound 1-e, 13mL acetonitrile is sequentially added into 100mL there-necked flask, 1.12g D6- benzaldehyde (Aldrich), 40.8mg trifluoroacetic acid, lower 35 DEG C of nitrogen protection are reacted 3 hours.Then 1.2mL 5%NaHCO is successively added dropwise3Solution and 5.3mL water, filtering, filter cake are successively washed with 8mL acetonitrile/water (2:1), and 2.85g gray solid, i.e. compound 9-a, yield 86% are obtained after vacuum drying.
1H-NMR(CDCl3, 300MHz): δ 7.28 (m, 1H), 7.23 (s, 1H), 7.08 (d, J=2.0Hz, 1H), 6.98 (dd, J=8.2,2.0Hz, 1H), 6.82 (m, 2H), 4.71 (d, J=8.9Hz, 1H), 3.52 (dd, J=15.7,8.9Hz, 1H), 3.12 (d, J=15.7Hz, 1H).
13C-NMR(CDCl3, 300MHz): δ 153.2,148.0,137.6,131.4,130.4,128.8,128.5,128.4,127.8,12 6.8,124.4,123.8,121.2,120.3,112.6,110.9,83.1,55.5,36.0.
HRMS (M+H) m/z:461.9970.
Bromo- 6- phenyl -6D- five deuterium benzoyl [5,6] [1,3] the oxygen azepine of step (2) (S) -3,10- twoThe preparation of [3,4-a] indoles
2.85g compound 9-a, 29mL DMA, 1.55g NaHCO are sequentially added into 100mL there-necked flask3, 10 DEG C are cooled to, in batches 1.86g potassium permanganate is added, then 7.2mL water is added dropwise, system temperature is kept to be lower than 15 DEG C, is reacted overnight for 10 DEG C after adding.57mL ethyl acetate is added, then 29mL NaHSO is added dropwise3Aqueous solution, stratification, water phase uses 30mL ethyl acetate to extract again, merges organic phase, is washed three times with 3 × 15mL 10%NaCl solution, gained organic phase is concentrated to get about 29mL aqueous isopropanol, it is added dropwise after 29mL water is stirred overnight and filters again, filter cake is washed with 12mL isopropanol/water (1:1), and 2.08g solid is obtained after vacuum drying, that is compound 9-b, yield 73.3%.
1H-NMR(CDCl3, 300MHz): δ 7.81 (d, J=1.8Hz, 1H), 7.51 (d, J=8.1Hz, 1H), 7.25-7.16 (m, 3H), 6.85 (s, 1H), 6.70 (d, J=8.8Hz, 1H), 6.90 (d, J=8.0Hz, 1H), 6.73 (d, J=8.0Hz, 1H), 4.94 (m, 1H), 4.40 (s, 1H), 3.30 (t, J=8.6Hz, 1H), 3.10 (dd, J=15.7,12.4Hz, 1H).
13C-NMR(CDCl3, 300MHz): δ 150.0,136.2,133.9,132.1,130.7,123.0,126.8,125.6,125.1,12 3.4,122.4,121.3,117.0,114.2,111.2,96.8,84.5.
HRMS (M+H) m/z:459.9814.
Step (3) (2S, 2 ' S)-di-t-butyl 2,2 '-(5,5 '-((S) -6- phenyl -6D- five deuterium benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles -3,10- diyl) two (1H- imidazoles -5,2- diyls)) two (pyrrolidines -1- formic acid esters) preparation
55mL Isosorbide-5-Nitrae-dioxane, 2.0g compound 9-b, 2.39g B (Pin) are sequentially added into 250mL there-necked flask2, 1.68g potassium acetate, 125.3mg Pd (dppf) Cl2, nitrogen protection it is lower 110 DEG C reaction 3 hours after cool, add 32mL Isosorbide-5-Nitrae-dioxane and 8mL water, 3.25g compound 1-h, 1.25g Pd (dppf) Cl2, 3.54g potassium carbonate, the lower 110 DEG C of reactions of nitrogen protection are overnight.The post-treated rear pillar chromatographic purifying (EA:PE=45:55) of reaction solution, obtains 2.05g yellow solid, i.e. compound 9-c, yield 61.5%.
1H-NMR (DMSO-d6,300MHz): δ 11.89 (m, 2H), 7.79 (d, 1H), 7.71 (s, 1H), 7.54-7.46 (m, 3H), 7.42-7.37 (m, 2H), 7.08 (s, 1H), 4.82 (m, 2H), 3.55 (br s, 2H), 3.37 (m, 2H), 2.32-2.10 (m, 2H), 2.08-1.83 (m, 6H), 1.41-1.16 (m, 18H).
13C-NMR (DMSO-d6,300MHz): δ 170.8,154.6,153.8,149.4,139.1,138.3,134.6,129.6,129.3,129.1,126.8,124.5,120.3,119.4,116.1,113.4,97.3,79.0,78.7,60.2,55.7,47.0,46.8,33.8,28.7,28.4,24.3,23.6,21.2,14.6.
HRMS (M+H) m/z:774.4075.
Step (4) 6- phenyl -3,10- two (2- ((S)-pyrrolidin-2-yl) -1H- imidazoles -5- base) -6D- five deuterium benzoyl [5,6] [1,3] oxygen azepineThe preparation of [3,4-a] indole hydrochloride
Sequentially add 2.0g compound 9-c, 11mL methanol into 50mL single port bottle, 2.0g concentrated hydrochloric acid, 45 DEG C are cooled to room temperature after reaction 4 hours, and 33mL acetonitrile is added dropwise, filters after being stirred overnight at room temperature, 1.7g solid, i.e. compound 9-d, yield 91.4% is obtained after vacuum drying.
1H-NMR (DMSO-d6,300MHz): δ 8.31 (d, J=0.7Hz, 1H), 8.19 (s, 1H), 8.05 (d, J=8.0Hz, 1H), 7.88 (s, 1H), 7.72 (m, 3H), 7.47 (d, J=8.8Hz, 1H), 5.16 (t, J=8.0Hz, 1H), 5.06 (t, J=8.0Hz, 1H), 3.52-3.37 (m, 4H), 2.57-2.47 (m, 5H), 2.24-2.17 (m, 2H), 2.08-1.91 (m, 2H).
13C-NMR (DMSO-d6,300MHz): δ 149.7,142.7,141.5,137.4,135.7,135.2,132.3,130.0,129.3,129.1,126.8,125.7,121.0,120.6,120.2,118.5,118.0,117.4,115.5,115.0,111.5,98.9,83.6,53.1,52.6,46.0,45.9,30.0,29.9,24.6,24.5.
HRMS (M+H) m/z:574.3203.
Step (5) dimethyl ((2S, 2 ' S)-((2S, 2 ' S) -2,2 '-(5,5 '-((S) -6- phenyl -6D- five deuterium benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles-3,10- diyl) two (1H- imidazoles-5,2- diyls)) two (pyrrolidines-2,1- diyls)) two (3- methyl-1-butanone-2,1- diyls)) dicarboxylic acid esters preparation
720mg compound 9-d, 8mL acetonitrile is sequentially added into 50mL two-mouth bottle, is cooled to 5 DEG C, 385mg N-Moc-L- valine, 708mg N-methylmorpholine is added, and 67.6mg HOBt, 421.7mg EDCHCl is reacted at room temperature overnight after adding.12mL ethyl acetate is added thereto, uses 6mL 2M NH respectively4Cl is washed, 4.5mL 10wt%NaHCO3It washes, 4.5mL 10wt%Na2CO3It washes, 4.5mL washing, the dry organic phase of anhydrous magnesium sulfate, concentration rear pillar chromatography (MeOH:DCM=3:100) obtains 686mg yellow solid, i.e. compound 9, yield 77.3%, purity 95.8%, 99%de.
1H-NMR (DMSO-d6,300MHz): δ 8.10 (s, 1H), 8.07 (d, J=8.4Hz, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.56-7.54 (m, 3H), 7.52 (d, J=8.7Hz, 1H), 7.35 (s, 1H), 6.97 (m, 2H), 5.16 (t, J=7.3Hz, 1H), 5.12 (t, J=7.3Hz, 1H), 4.15-4.11 (m, 2H), 3.91-3.80 (m, 4H), 3.55 (s, 3H), 3.54 (s, 3H), 2.45-2.36 (m, 2H), 2.02-1.98 (m, 8H) 0.85 (d, J=6.8Hz, 3H), 0.82 (d, J=6.8Hz, 3H), 0.80 (d, J=6.8Hz, 3H), 0.77 (d, J=6.8Hz, 3H).
13C-NMR (DMSO-d6,300MHz): δ 170.8,157.3,149.9,149.4,138.7,138.1,136.9,134.4,131.9,130.1,129.6,129.3,129.1,126.8,124.6,120.2,119.3,116.1,115.9,113.8,113.5,111.4,110.3,97.1,58.5,58.4,55.4,54.7,51.9,47.3,31.4,30.3,24.7,24.6,19.5,19.4,19.1,19.0.
HRMS (M+H) m/z:888.4613.
The preparation of 3 compound 7 of embodiment
The preparation of step (1) D1- benzaldehyde
150mL ether is sequentially added into 500mL there-necked flask, 62.8g chloroacetic chloride is added dropwise in 37.92g anhydrous stannous chloride, -10 DEG C are cooled to, -10 DEG C of dropwise addition 15.02g heavy water add 10.3g benzonitrile, add room temperature reaction overnight, filtering, filter cake are dried in vacuo to obtain 22.45g white solid, make its hydrolysis with 250ml hot water, it is concentrated after ether extraction dry, obtain 7.2g liquid, yield 67.3%, purity 99%.
Bromo- 6- phenyl -12,12a- dihydro -6D- benzoyl [5,6] [1,3] the oxygen azepine of step (2) (S, 12aR) -3,10- twoThe preparation of [3,4-a] indoles
7.38g compound 1-e, 30mL acetonitrile is sequentially added into 100mL there-necked flask, 3g D1- benzaldehyde, 114mg trifluoroacetic acid, lower 35 DEG C of nitrogen protection are reacted 3 hours.Then 3.3mL 5%NaHCO is successively added dropwise3Solution and 15mL water, filtering, filter cake are successively washed with 22.5mL acetonitrile/water (2:1), and 7.69g gray solid, i.e. compound 7-a, yield 84% are obtained after vacuum drying.
1H-NMR(CDCl3, 500MHz): δ 7.55 (m, 2H), 7.54-7.25 (m, 4H), 7.19 (d, 1H), 7.06 (dd, 1H), 6.97-6.82 (m, 1H), 6.81-6.78 (m, 2H), 4.68 (d, 1H), 4.69 (dd, 1H), 3.52 (m, 1H), 3.11 (d, 1H).
13C-NMR(CDCl3, 500MHz): δ 153.4,148.2,137.8,131.6,130.6,129.0,128.7,128.0,127.0,12 4.6,124.0,121.4,120.5,112.8,110.0,83.1,55.7,36.2.
HRMS (M+H) m/z:456.9898.
Bromo- 6- phenyl -6D- benzoyl [5,6] [1,3] the oxygen azepine of step (3) (S) -3,10- twoThe preparation of [3,4-a] indoles
7.6g compound 7-a, 76mL DMA, 4.18g NaHCO are sequentially added into 500mL there-necked flask3, 10 DEG C are cooled to, 5.01g potassium permanganate is added portionwise, then 19mL water is added dropwise, system temperature is kept to be lower than 15 DEG C, 10 DEG C of reactions are stayed overnight after adding.152mL ethyl acetate is added, then 76mL NaHSO is added dropwise3Aqueous solution, stratification, water phase use 80mL ethyl acetate to extract again, merge organic phase, it is washed three times with 3 × 40mL 10%NaCl solution, is concentrated after washing, about 120ml isopropanol is added, it is concentrated to get about 76mL aqueous isopropanol, it is added dropwise after 76mL water is stirred overnight and filters again, filter cake is washed with 32mL isopropanol/water (1:1), and 6.387g solid is obtained after vacuum drying, that is compound 7-b, yield 84.4%.
1H-NMR(CDCl3, 500MHz): δ 7.78 (d, 1H), 7.51 (d, 1H), 7.34-7.29 (m, 3H), 7.29-7.28 (m, 3H), 7.06 (d, 2H), 6.83 (s, 1H), 6.70-6.68 (d, 1H).
13C-NMR(CDCl3, 500MHz): δ 150.2,136.3,134.1,132.3,130.9,130.1,129.1,127.0,126.6,12 5.7,125.2,123.6,122.6,121.5,117.2,114.3,111.3,97.0.
HRMS (M+H) m/z:454.9389.
Step (4) (2S, 2 ' S)-di-t-butyl 2,2 '-(5,5 '-((S) -6- phenyl -6D- benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles -3,10- diyl) two (1H- imidazoles -5,2- diyls)) two (pyrrolidines -1- formic acid esters) preparation
80mL Isosorbide-5-Nitrae-dioxane, 3g compound 7-b, 3.63g B (Pin) are sequentially added into 250mL there-necked flask2, 2.54g potassium acetate, 190mg Pd (dppf) Cl2, nitrogen protection it is lower 110 DEG C reaction 3 hours after cool, add 48mL Isosorbide-5-Nitrae-dioxane and 12mL water, 4.93g compound 1-h, 1.9g Pd (dppf) Cl2, 5.37g potassium carbonate, the lower 110 DEG C of reactions of nitrogen protection are overnight.The post-treated rear pillar chromatographic purifying (EA:PE=45:55) of reaction solution, obtains 3.22g yellow solid, i.e. compound 7-c, yield 64.3%.
1H-NMR (DMSO-d6,500MHz): δ 11.95 (m, 2H), (7.98 d, 1H), 7.78 (s, 1H), 7.54-7.46 (m, 3H), (7.42-7.37 m, 2H), 7.30-7.27 (m, 4H), 7.08 (s, 1H), (4.82 m, 2H), 3.55 (br s, 2H), 3.37 (m, 2H), 2.32-2.10 (m, 2H), 2.08-1.83 (m, 6H), 1.41-1.16 (m, 18H).
13C-NMR (DMSO-d6,500MHz): δ 170.8,154.6,153.8,149.4,139.1,138.3,134.6,129.6,129.3,129.1,126.8,124.5,120.3,119.4,116.1,113.4,97.3,79.0,78.7,60.2,55.7,47.0,46.8,33.8,28.7,28.4,24.3,23.6,21.2,14.6.
HRMS (M+H) m/z:769.3926.
Step (5) 6- phenyl -3,10- two (2- ((S)-pyrrolidin-2-yl) -1H- imidazoles -5- base) -6D- benzoyl [5,6] [1,3] oxygen azepineThe preparation of [3,4-a] indole hydrochloride
1.7g compound 7-c, 8.5mL methanol, 1.3g concentrated hydrochloric acid are sequentially added into 50mL single port bottle, 45 DEG C reaction 4 hours after be cooled to room temperature, be added dropwise 50mL acetonitrile, filtered after being stirred overnight at room temperature, 1.35g solid, i.e. compound 7-d, yield 85.5% are obtained after vacuum drying.
1H-NMR (DMSO-d6,500MHz): δ 8.31 (d, 1H), 8.18 (m, 2H), 8.05 (d, 1H), 7.70 (m, 3H), 7.48 (d, 1H), 7.32 (m, 4H), 7.02 (m, 2H), 5.15 (t, 1H), 5.04 (t, 1H), 3.39-3.37 (m, 4H), 2.57-2.47 (m, 5H), 2.24-2.17 (m, 2H), 2.08-1.91 (m, 2H)
13C-NMR (DMSO-d6,500MHz): δ 149.7,142.7,141.5,137.4,135.7,135.2,132.3,130.0,129.3,12 9.1, 126.8,125.7,121.0,120.6,120.2,118.5,118.0,117.4,115.5,115.0,111.5,98.9,83.6,53.1,52.6,46.0,45.9,30.0,29.9,24.6,24.5。
HRMS (M+H) m/z:569.2869.
Step (6) dimethyl ((2S, 2 ' S)-((2S, 2 ' S) -2,2 '-(5,5 '-((S) -6- phenyl -6D- benzoyl [5,6] [1,3] oxygen azepines[3,4-a] indoles-3,10- diyl) two (1H- imidazoles-5,2- diyls)) two (pyrrolidines-2,1- diyls)) two (3- methyl-1-butanone-2,1- diyls)) dicarboxylic acid esters preparation
1000mg compound 7-d, 10mL acetonitrile is sequentially added into 50mL two-mouth bottle, is cooled to 5 DEG C, 539mg N-Moc-L- valine, 992mg N-methylmorpholine is added, and 95mg HOBt, 590mg EDCHCl is reacted at room temperature overnight after adding.17mL ethyl acetate is added thereto, uses 8.3mL 2M NH respectively4Cl is washed, 6.3mL 10wt%NaHCO3It washes, 6.3mL 10wt%Na2CO3It washes, 6.3mL washing, the dry organic phase of anhydrous magnesium sulfate, concentration rear pillar chromatography (MeOH:DCM=3:100) obtains 1.02mg yellow solid, i.e. compound 7, yield 82.4%, purity 96.7%, 99%de.
1H-NMR (DMSO-d6,500MHz): δ 8.10 (s, 1H), 8.07 (d, J=8.4Hz, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.56-7.54 (m, 3H), 7.52 (d, J=8.7Hz, 1H), 7.35 (s, 1H), 7.31-7.27 (m, 5H), 6.97 (m, 2H), 5.16 (t, J=7.3Hz, 1H), 5.12 (t, J=7.3Hz, 1H), 4.15-4.11 (m, 2H), 3.91-3.80 (m, 4H), 3.55 (s, 3H), 3.54 (s, 3H), 2.45-2.36 (m, 2H) 2.02-1.98 (m, 8H), 0.85 (d, J=6.8Hz, 3H), 0.82 (d, J=6.8Hz, 3H), 0.80 (d, J=6.8Hz, 3H), 0.77 (d, J=6.8Hz, 3H).
13C-NMR (DMSO-d6,500MHz): δ 170.8,157.3,149.9,149.4,138.7,138.1,136.9,134.4,131.9,130.1,129.6,129.3,129.1,126.8,124.6,120.2,119.3,116.1,115.9,113.8,113.5,111.4,110.3,97.1,58.5,58.4,55.4,54.7,51.9,47.3,31.4,30.3,24.7,24.6,19.5,19.4,19.1,19.0.
HRMS (M+H) m/z:883.4388.
The external anti-hepatovirus activity rating of effect example 1
Experimental method:
Test compound carries out 1:3 and is serially diluted 8 concentration points, and duplicate hole is added in 96 orifice plates.HCV GT-1a and HCV GT-1b replicon cell is suspended in respectively in the culture solution containing 10%FBS, is inoculated into 96 orifice plates containing the test compound with the density of every 8000 cells in hole.CO of the cell 5%2, cultivate 3 days under the conditions of 37 DEG C.Cell viability detection reagent is added, detects fluorescence signal (RFU, cell viability initial data) after 1 hour.Then, luciferase luminous substrate Bright-Glo is added into every hole cell, detects chemiluminescence signal value RLU with chemiluminescence detection system after five minutes.Initial data RFU and RLU are analyzed, the percent viability and test compound for calculating HCV GT-1a and HCV GT-1b replicon cell are to the inhibitory activity percentage of HCV GT-1a and HCV GT-1b genocopy.Nonlinear fitting is carried out to inhibitory activity and cell viability percentage data using GraphPad Prism software, calculates the EC of compound50And CC50。
Experimental result:
Elbasvir, compound 1, compound 9 inhibit the CC of cell viability in vitro50It is all larger than 0.5nM, to the EC of the sub- inhibitory activity of HCV GT-1a genocopy50Respectively 0.004,0.005,0.004nM (being shown in Table 1), to the EC of the sub- inhibitory activity of HCV GT-1b genocopy50Respectively 0.005,0.005,0.003nM (being shown in Table 2).
1 Compound ira vitro cytotoxicity of table and anti-hepatitis C virus are active (HCV GT-1a)
2 Compound ira vitro cytotoxicity of table and anti-hepatitis C virus are active (HCV GT-1b)
The external people's hepatomicrosome estimation of stability of effect example 2
It is incubated in system in the final temperature of 300 μ L, contains 30 μ L people hepatomicrosomes (protein concentration: 0.15mg/mL), 30 μ L NADPH+MgCl2, 3 μ L substrates, 237 μ L PBS buffer solution.Wherein, the ratio of organic solvent (acetonitrile) is 1%.2 parts are done in parallel, every part of 0.3mL.For every part of sample, 30 μ L NADPH+MgCl are added with NADPH respectively after 37 DEG C of pre-temperatures incubate 5min in the mixing liquid for first preparing substrate and enzyme that total volume is 270 μ L2Mixing, takes out 40 μ L respectively at 0,5,15,30,60,120min, terminates reaction with the 300 μ L of ice acetonitrile of containing the internal standard.In addition, being 3 parts of each 300 μ L of blank (KB) respectively, NADPH respectively KB1: is not added；KB2: substrate is not added；KB3: not enzyme.
It draws 40 μ L temperature and incubates sample, the ice acetonitrile precipitation of 300 μ L containing the internal standards is added, be vortexed after concussion 5min, be centrifuged (13000rpm, 4 DEG C) 10min.80 μ L of Aspirate supernatant is added 80 μ L, 50% acetonitrile solution, mixes, sample introduction is analyzed by 0.5 μ L to sample introduction plate.
It is mapped by the Ln value of each time point residue test compound percentage and time, t is calculated by respective formula1/2And CLint。
Slope=- Kmic
Note: V/M=1/ protein concentration
Table 3 shows the test data of the external people's hepatomicrosome metabolic stability of test compound.
The external people's hepatomicrosome metabolic stability of 3 test compound of table
The result shows that external people's hepatomicrosome metabolic stability of the compound of the present invention 1 and compound 9 is more excellent compared with elbasvir.
Pharmacokinetic Evaluation in 3 rat of effect example
SD rat, 200~220g of weight are randomly divided into 2 groups, every group 3, give test compound elbasvir, the compound 7 of 10mg/kg dosage respectively after adapting to 3-5 days.
Fasting 12h before animal subject (SD rat) is administered, 4h is to food, experiment front and back and equal free water in experimentation after administration.
After gastric infusion, in 0min, 15min, 30min, 1h, 3h, 4h, 5h, 6h, 8h, 10h, for 24 hours in eye socket blood 0.10mL or so is taken, EDTA-K2 is anticoagulant, immediately places blood sample in ice, 4 DEG C are transferred in 30min, centrifugal separation plasma under the conditions of 4000rpm, 10min.It is to be measured in -20 DEG C of preservations immediately after the whole blood plasma of collection.
Draw 40 μ L test plasma samples and standard sample, the acetonitrile solution of 200 μ L containing the internal standards is added, oscillation mixes 5min, 13000rpm is centrifuged 10min, take 80 μ L of supernatant to sample introduction plate, 80 μ L, 50% acetonitrile solution is added, mixes, draws 1 μ L for LC-MS/MS and measures (liquid-phase condition: chromatographic column: ACQUITY UPLC BEH C18 (1.7 μm of 2.1 × 50mm)；Water phase: 0.1% aqueous formic acid, organic phase: methanol solution；Flow velocity: 0.3ml/min, gradient condition: the ratio 0-0.5min:90% of water phase；0.5-0.8min:90%~40%；0.8-1.2min:40%~5%；1.2-2.0min:5%；2.0-2.2min:5%~90%；2.2-3.0min:90%.Mass Spectrometry Conditions: it is detected using LC-MS/MS (Waters TQ-S), ion source: ESI+, orifice potential: 85V, capillary voltage: 3.2kV, ion source temperature: 150 DEG C, desolvation temperature: 400 DEG C, desolvation gas flow velocity: 800L/hr.The selective reaction of Elbasvir detects ion [M+H] m/z 882.5 → 656.42, and the selective reaction of compound 7 detects ion [M+H] m/z 883.43 → 657.37.Internal standard diazepam selective reaction detects m/z285.06 → 154.04 ion [M+H]), record chromatogram.
Pass through the oral administration biaavailability of Rats pharmacokinetics experimental evaluation the compounds of this invention.
The medicine of 4 test compound of table is for parameter

Claims (12)

  1. One kind such as formula Ι compound represented or its pharmaceutically acceptable salt:
    Wherein, R1Or R2Separately it is selected from CH3、CH2D、CHD2Or CD3, R3、R4、R5、R6、R7、R8Or R9It is independently selected from H or D, condition is R1~R9In contain at least one D-atom.
  2. The compound of claim 1, wherein R1、R2It is simultaneously CH3Or CD3。
  3. The compound of claim 1, wherein R5、R6、R7、R8、R9It is simultaneously H or D.
  4. The compound of claim 1, wherein such as formula Ι compound represented are as follows:
    Compound R1 R2 R3 R4 R5 R6 R7 R8 R9 1 CD3 CD3 H H H H H H H 2 CD3 CD3 D H H H H H H 3 CD3 CD3 H D H H H H H 4 CD3 CD3 D H D D D D D 5 CD3 CD3 D D H H H H H 6 CD3 CD3 D D D D D D D 7 CH3 CH3 D H H H H H H 8 CH3 CH3 D D H H H H H 9 CH3 CH3 D H D D D D D 10 CH3 CH3 D D D D D D D 11 CH3 CH3 H D H H H H H
  5. The compound of claim 1, wherein such as formula Ι compound represented are as follows:
  6. A kind of pharmaceutical composition, it includes compound of any of claims 1-5 or its pharmaceutically acceptable salts and pharmaceutically acceptable excipient.
  7. The purposes of compound of any of claims 1-5 or its pharmaceutically acceptable salt, pharmaceutical composition as claimed in claim 6 in the drug of preparation prevention or treatment hepatitis c virus infection.
  8. The purposes of claim 7, wherein the hepatitis C virus is selected from following genotype: 1a, 1b, 2a, 2b, 3a, 3b, 4a, 5a or 6a.
  9. For preventing or treating the pharmaceutical composition containing compound of any of claims 1-5 or its pharmaceutically acceptable salt of hepatitis c virus infection.
  10. The pharmaceutical composition of claim 9, wherein the hepatitis C virus is selected from following genotype: 1a, 1b, 2a, 2b, 3a, 3b, 4a, 5a or 6a.
  11. A method of prevention or treatment hepatitis c virus infection, wherein, the method includes compound of any of claims 1-5 or its pharmaceutically acceptable salt, the pharmaceutical composition containing compound shown in formula I or its pharmaceutically acceptable salt are given to the patient of needs.
  12. The method of claim 11, wherein the hepatitis C virus is selected from following genotype: 1a, 1b, 2a, 2b, 3a, 3b, 4a, 5a or 6a.
CN201680072055.0A 2015-12-10 2016-12-09 Deuterium modified elbasvir derivatives, pharmaceutical compositions containing the same and uses thereof Active CN108290904B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510917008 2015-12-10
CN2015109170089 2015-12-10
PCT/CN2016/109181 WO2017097253A1 (en) 2015-12-10 2016-12-09 Deuterium-modified elbasvir derivative, drug composition containing same, and use thereof

Publications (2)

Publication Number Publication Date
CN108290904A true CN108290904A (en) 2018-07-17
CN108290904B CN108290904B (en) 2020-10-09

Family

ID=59012621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072055.0A Active CN108290904B (en) 2015-12-10 2016-12-09 Deuterium modified elbasvir derivatives, pharmaceutical compositions containing the same and uses thereof

Country Status (2)

Country Link
CN (1) CN108290904B (en)
WO (1) WO2017097253A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232612A (en) * 2017-07-11 2019-01-18 周龙兴 Inhibit compound, the medical composition and its use of hepatitis C virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040923A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012041014A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
CN104230946A (en) * 2013-06-06 2014-12-24 爱博新药研发(上海)有限公司 Compounds for inhibiting hepatitis C virus, pharmaceutical compositions of compounds and applications of pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040923A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012041014A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
CN104230946A (en) * 2013-06-06 2014-12-24 爱博新药研发(上海)有限公司 Compounds for inhibiting hepatitis C virus, pharmaceutical compositions of compounds and applications of pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王浩丹 等: "《生物医学标记示踪技术》", 31 December 1995, 人民卫生出版社 *

Also Published As

Publication number Publication date
WO2017097253A1 (en) 2017-06-15
CN108290904B (en) 2020-10-09

Similar Documents

Publication Publication Date Title
US6930106B2 (en) Inhibitors of HCV NS5B polymerase
CN108658983B (en) N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof
WO2020020267A1 (en) Substituted polycyclic pyridone compound and prodrug thereof
CN108473477A (en) The pyrimidine of aryl substitution for being used in influenza infection
CN106467495A (en) Pyridazinone compound, its preparation method, pharmaceutical composition and purposes
CN110092779B (en) Substituted phenyl compound and application thereof
EP2350039A1 (en) Viral polymerase inhibitors
CN106892920A (en) Aloperine derivative, Preparation Method And The Use
KR102434764B1 (en) Hepatic Transmission Antiviral Precursor Drug Nucleoside Cyclophosphate Ester Compounds and Applications
WO2017206955A1 (en) Applications of novel thiazole derivative in treating virus infection
CN109790123A (en) Novel capsid protein assembles inhibitor
JP7250015B2 (en) Anti-HBV tetrahydroisoxazolo[4,3-c]pyridine class compounds
CN101684098A (en) 5-lipoxygenase inhibitor and preparation method, medical composite and application thereof
CN102149678A (en) Novel ortho-aminoanilides for the treatment of cancer
CN112771048B (en) Inhibitors of influenza virus replication and intermediates and uses thereof
CN108290904A (en) Elbasvir derivatives, the medical composition and its use containing the compound of deuterium modification
CN108794517A (en) A kind of arginase inhibitor and preparation method thereof and purposes
RU2761825C1 (en) Deuterated defactinib compounds and their application
CN108129366B (en) Antiviral compounds, methods of preparation and uses thereof
WO2013004141A1 (en) 3-alkoxy-substituted-2-pyrazinyl formamide compound and use thereof
CN102633796A (en) New preparation method of sophora flavescens acid derivative
CN106831532B (en) It is complete to replace 3- nitroindoline compound and its midbody compound, preparation method and application
CN114920663B (en) Biphenyl oseltamivir derivative and preparation method and application thereof
JP6923112B2 (en) Biarylsulfonamide derivative with filovirus cell invasion inhibitory activity
CN100357284C (en) Compounds against influenza virus and their preparing process and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant